Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy
نویسندگان
چکیده
منابع مشابه
Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
BACKGROUND Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib. PATIENTS AND METHODS Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined. RESULTS Best obje...
متن کاملCombination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
BACKGROUND Regorafenib has been demonstrated as effective in refractory metastatic colorectal cancer. Combination use with chemotherapy has not been reported. We examined the efficacy and safety of adding chemotherapy to Regorafenib for the treatment of metastatic colorectal cancer(mCRC) patients. METHODS We recruited mCRC patients at our institute who received either regorafenib monotherapy ...
متن کاملFDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
“Stivarga is the latest colorectal cancer treatment to demonstrate an ability to extend patients’ lives, and is the second drug approved for patients with colorectal cancer in the past 2 months,” said Richard Pazdur, MD, director of the office of hematology and oncology products in FDA’s Center for Drug Evaluation and Research, in a press release. In August, the FDA approved aflibercept (Zaltra...
متن کاملMeeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
Colorectal cancer is a global issue, affecting men and women equally. Over the last 25 years, advances in therapy and multidisciplinary care have led to improvements in survival for those with colorectal cancer. Despite these advances, more therapeutic options are needed for those being treated for this disease. Regorafenib is an oral drug that is a new therapeutic option for our patients. The ...
متن کاملEarly morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
Background and Objective It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib. Results This study evaluated 68 patients. Among 52 patients with lung metastasis, 16 (31%) had cavity formation (CF). ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Biology & Therapy
سال: 2015
ISSN: 1538-4047,1555-8576
DOI: 10.1080/15384047.2015.1113355